GPC3 and neoplasm: Indeed, genetically altered MSCs expressing a fusion protein of the exosome membrane protein Lamp2b and a single-chain variable fragment (scFv) specific to the hepatocellular carcinoma (HCC) marker Glypican-3 (GPC3) were successfully used to specifically deliver the biopharmaceutical cargo miR-26a to GPC3-positive cancer cells both in vitro and in vivo, which resulted in cell cycle arrest via downregulation of cyclin D2 and E2, respectively, and, consequently, inhibited tumor cell proliferation [145].